The safety of mTOR inhibitors during pregnancy in LAM has not yet been established, and they are classified as category C; that is, they have unknown fetal teratogenicity and their use is not an absolute contraindication.166. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.